市場調查報告書
商品編碼
1371898
2030 年 3D 細胞培養市場預測:按產品、用途、最終用戶和地區進行的全球分析3D Cell Culture Market Forecasts to 2030 - Global Analysis By Product (Scaffold-based 3D Cell Cultures, Scaffold-Free 3D Cell Cultures, 3D Bioreactors and 3D Petri Dishes), Application, End User and By Geography |
根據 Stratistics MRC 的數據,2023 年全球 3D 細胞培養市場規模為 13 億美元,預計在預測期內年複合成長率為 16.6%,到 2030 年將達到 38 億美元。
3D(3D)細胞培養是細胞生物學和組織工程領域用於在3D環境中培養和研究細胞的實驗技術。在3D (3D) 細胞培養中,細胞在類似身體組織或器官的實際3D (3D) 結構的基質或支架內生長。3D細胞培養與人體中複雜的細胞連結和組織結構非常相似,有利於研究細胞活性、藥物反應和疾病原因。
根據美國國立衛生研究院的數據,2020 年各種生物工程技術的總投資達 5,646 美元,高於 2019 年的 5,091 美元。這些要素正在擴大美國3D 細胞培養市場。
技術的發展、對更接近活體生物體的體外模型的需求不斷增加,以及在藥物研發、再生醫學、癌症研究等方面的應用,都促進了 3D 細胞培養市場的成長。與傳統的 2D 細胞培養相比,3D 細胞培養技術為研究細胞行為和組織發育提供了更生理相關的環境。因此,尋求更精確方法進行臨床實驗的研究人員擴大使用它。癌症、心血管疾病和神經系統疾病等慢性疾病的患病不斷上升,推動了對 3D 細胞培養輔助下更有效的藥物開發和疾病建模的需求。
建構和維護 3D 細胞培養系統可能比傳統的 2D 培養更困難。許多系統和實驗室很難保持一致性,這可能會損害結果的再現性和可比性。擴大 3D 細胞培養系統的規模以進行高通量篩選或大規模生產可能很困難。對於藥品製造等用途來說,確保大規模的可靠結果是阻礙市場成長的挑戰。
動物實驗經常用於製藥和科學研究,以探索無法使用簡單的二維 (2D) 細胞培養物進行研究的複雜生物過程。另一方面,僅使用動物模型進行藥物測試和毒性篩檢的倫理和科學限制日益受到重視。歐洲藥品管理局 (EMA) 和美國食品藥物管理局(FDA) 等法規機構正在推動 3D 細胞培養的開發和部署,用於全球藥物篩選和安全評估。例如,透過FDA的預測毒理學路線圖,政府鼓勵使用尖端的體外模型,例如3D細胞培養,以提高毒性測試的準確性和有效性。更嚴格的法規要求和更少的動物實驗
然而,3D細胞培養的高成本是市場拓展的主要障礙。 3D 細胞培養技術的入門價格可能會因許多變數而異,包括系統複雜性、產量和應用的特殊需求。根據所需的複雜性和功能,這些設備的價格從幾千美元到數十萬美元不等。由於成本較高,3D細胞培養被大型研究機構和製藥公司採用。這可能會限制小型研究團隊或單獨工作的研究人員使用該技術,從而可能抑制市場。
研究COVID-19的研究人員如果能夠未來性適合3D細胞培養和/或氣液界面培養的基質,應該使用治療方法,有必要探索試管內細胞培養的系統效應機制。這是使用 3D 細胞培養進行 COVID-19 研究的主要理由。這項研究還發現,類器官和球體培養等方法可以提供必要的型態和生化特徵,以便在無法進行 2D 培養的情況下支持病毒感染。這些方法也比 2D 培養更準確地再現病毒感染系統。
基於支架的 3D 細胞培養部分預計將有良好的成長。支架提供了類似身體組織和器官中存在的細胞外基質(ECM)的結構框架。這種結構支持有助於維持培養物的3D (3D) 結構,這對於細胞黏合、遷移和組織發育是必需的。借助支架,細胞可以以更有系統的方式與周圍環境進行交流和互動。隨著研究人員透過改變支架的硬度、孔隙率和成分來調節細胞發育的微環境,現在可以分析細胞-細胞和細胞-基質相互作用以及組織特異性功能。這使得精確改變培養條件以檢查不同的細胞反應成為可能,從而推動市場成長。
組織工程是一個尋求開發用於移植、修復和替換的功能性組織和器官的領域,並且嚴重依賴3D細胞培養,這就是為什麼組織工程領域在預測期內將出現最高的年複合成長率(CAGR )。組織工程的目標是利用 3D 細胞培養的原理在目標組織和器官中重建體內條件。細胞被接種在支架上和支架內,其中許多是來自患者的幹細胞或原代細胞。根據所創建的目標器官或組織,這些細胞源自多種組織,在 3D 培養環境中,細胞經歷與體內發生的過程非常相似的分化和成熟過程。
由於美國專注於研發並最近在 3D 細胞培養研究方面進行了大量投資,預計北美將在預測期內佔據最大的市場佔有率。結果是技術改進。許多美國都是 3D 細胞培養領域的頂尖專利申請者之一。大多數美國候選人都在美國和亞洲進行創新。近年來,美國生物技術產業也得到了大量投資。還需要在試管內模擬人類生理、疾病和藥物反應的複雜方面。隨著器官移植需求的增加,對 3D 細胞培養的需求也預計會增加。
由於製藥和生物技術公司以及學術研究中心等歐洲主要最終用戶行業的採用強勁,預計 3D 細胞培養產品的採用將在預測期內實現最高的年複合成長率。這一趨勢預計在未來年度將持續下去,但也是由製藥和生物技術領域的擴張、基於微流體技術的產品最近的商業化、主要市場參與者的不斷增加以及該領域資源的豐富所推動的。由於研究活動,領域這些產品的使用率會更高。
Thermo Fisher Scientific 於 2023 年 8 月完成對 CorEvitas 的收購。資料透過常規臨床護理資料的患者醫療保健利用率和結果數據的收集和使用。
2023 年 6 月,BD 推出新的機器人系統以實現臨床流式細胞儀自動化。BD FACSDuet(TM) Premium 樣品製備系統利用液體處理機器人來自動化整個樣品製備過程。
According to Stratistics MRC, the Global 3D Cell Culture Market is accounted for $1.3 billion in 2023 and is expected to reach $3.8 billion by 2030 growing at a CAGR of 16.6% during the forecast period. Three-dimensional (3D) cell culture is a laboratory technique used in the fields of cell biology and tissue engineering to grow and study cells in a three-dimensional environment. In three-dimensional (3D) cell culture, cells are developed within a matrix or scaffold that resembles the bodily tissues' and organs' actual three-dimensional (3D) structures. For the purpose of researching cell activity, medication responses, and disease causes, 3D cell culture is more advantageous since it more closely resembles the intricate cellular connections and tissue structures present in the human body.
According to the National Institute of Health, in 2020, the total investment in various bio engineering technologies amounted to USD 5,646, an increase from USD 5,091 in 2019. These factors have augmented the US 3D cell culture market.
Technology developments, rising need for in vitro models that more closely resemble in vivo settings, applications in drug discovery, regenerative medicine, and cancer research, among other factors, have all contributed to the growth of the 3D cell culture market. Comparatively to conventional 2D cell culture, 3D cell culture techniques provide a more physiologically appropriate environment for researching cell behavior and tissue development. As a result, usage has grown as researchers look for ways to make their trials more accurate. The need for more efficient drug development and disease modeling, which 3D cell culture can help, has been pushed by the rising prevalence of chronic diseases like cancer, cardiovascular diseases, and neurological disorders, among others.
The creation and upkeep of 3D cell culture systems can be more difficult than conventional 2D culture. It can be difficult to achieve uniformity across many systems and laboratories, which could impede the repeatability and comparability of results. It can be difficult to scale up 3D cell culture systems for high-throughput screening or large-scale production. For applications like medication manufacturing, ensuring reliable results at bigger scales is a challenge which hampers the growth of the market.
In order to explore complicated biological processes that cannot be studied with a straightforward two-dimensional (2D) cell culture, animal studies are frequently used in pharmaceutical and scientific research. The ethical and scientific limits of using just animal models for drug testing and toxicity screening, on the other hand, have come under increasing scrutiny. Regulatory agencies including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have pushed for the global development and deployment of 3D cell culture for drug screening and safety assessment. For instance, the government encourages the use of cutting-edge in vitro models, such as 3D cell cultures, to increase the precision and effectiveness of toxicity testing via the FDA's Predictive Toxicology Roadmap. The tightening of regulatory requirements and the decline in animal testing
The expensive expense of 3D cell culture, however, poses a significant obstacle to the market's expansion. The price of implementing 3D cell culture technologies might differ based on a number of variables, including the system's complexity, the volume of production, and the application's particular needs. Depending on the complexity and functionality needed, the price of these instruments can range from a few thousand dollars to several hundred thousand dollars. Because it is expensive, 3D cell culture is used by big research organizations and pharmaceutical firms. This may restrict access to this technology for smaller research teams and lone researchers thus impeding the market.
In order to evaluate prospective treatments in a physiological milieu, researchers working on COVID-19 who have access to appropriate matrices for 3D cell culture and suitable for air-liquid interface culture must first explore in vitro the mechanisms of the systemic effects of cell cultures. This is the main justification for using 3D cell cultures in COVID-19 research. The study also discovered that methods like organoids and spheroid cultures may provide the morphology and biochemical characteristics necessary to support viral infection in situations where 2D cultures cannot. These methods also reproduce viral infection systems more accurately than 2D cultures can.
The scaffold-based 3D cell cultures segment is estimated to have a lucrative growth, as these Scaffolds offer a structural framework that resembles the extracellular matrix (ECM) present in bodily tissues and organs. This structural support aids in preserving the culture's three-dimensional (3D) architecture, which is necessary for cell adhesion, migration, and tissue development. Cells can communicate and interact with their surroundings more systematically thanks to scaffolds. The analysis of cell-cell and cell-matrix interactions as well as tissue-specific functions is made possible by the researchers who can alter the stiffness, porosity, and composition of scaffolds to regulate the microenvironment in which cells develop. This makes it possible to precisely alter the culture conditions in order to investigate diverse cellular reactions which drive the growth of the market.
The tissue engineering segment is anticipated to witness the highest CAGR growth during the forecast period, as tissue engineering, a discipline that seeks to develop functional tissues and organs for transplantation, repair, and replacement, heavily relies on 3D cell culture. The goal of tissue engineering is to replicate the in vivo conditions of the target tissue or organ using the principles of 3D cell culture. Cells are sown onto or inside the scaffold, frequently stem cells or primary cells from the patient. Depending on the target organ or tissue being created, these cells might come from a variety of tissues and cells go through differentiation and maturation processes in the 3D culture environment that closely resemble those that take place in vivo.
North America is projected to hold the largest market share during the forecast period owing to the United States is concentrating on R&D and has recently made large investments in research into 3D cell culture. The nation has seen technological improvements as a result. Among the top patent applications for the field of 3D cell culture are numerous Americans. The majority of American candidates develop their innovations both here and in Asia. Over the past few years, there have also been large investments made in the bioengineering industry in the United States. In vitro mimicry of complex aspects of human physiology, disease, and drug reactions is also necessary. The need for 3D cell cultures is anticipated to increase as the need for organ transplantation rises in the area.
Europe is projected to have the highest CAGR over the forecast period, owing to the adoption of 3D cell culture products is strong in Europe's key end-user industries, including pharmaceutical and biotechnology firms and academic research centers. Although this trend is anticipated to continue in the upcoming years, moreover the higher uptake of these products due to the expansion of the pharmaceutical and biotechnology sectors, the recent commercialization of products based on microfluidic technology, the growing presence of key market players, and the abundance of research activities in the area.
Some of the key players profiled in the 3D Cell Culture Market include: BiomimX SRL, Hurel Corporation, CN Bio Innovations, InSphero AG, Corning Incorporated, Lonza AG, MIMETAS BV, Merck KGaA, Thermo Fisher Scientific, Nortis Inc., Advanced Biomatrix, Inc., Avantor, Inc., Becton, Dickinson And Company, Lena Biosciences, Promocell GmbH, REPROCELL Inc., Sartorius AG, Synthecon Incorporated, Tecan Trading AG, Nanofiber Solutions
In August 2023, Thermo Fisher Scientific Completes Acquisition of CorEvitas Real-world evidence is the collection and use of patient health care utilization and outcomes data gathered through routine clinical care.
In June 2023, BD Launches New Robotic System to Automate Clinical Flow Cytometry. The BD FACSDuet™ Premium Sample Preparation System leverages liquid-handling robotics to automate the entire sample preparation process.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.